tirzepatide clinical trial SURMOUNT-3 study design This is a phase 3, multicenter, randomized, Alternative dosing regimens of GLP-1
Description
These appointments allow your provider to monitor your progress, adjust your dose if needed, and address any concerns you may have
Future Perspectives on GLP-1 Receptor Agonists and GLP-1/Glucagon Receptor Co-agonists in the Treatment of NAFLD
administered tirzepatide vs s.c
Patients start with a lower dose, which is gradually increased over several months to the full Wegovy dose 2.4 mg
Access this article Similar content being viewed by others Availability of data & material Not applicable
Some doctors remain skeptical of pharmacological weight management
